Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 174

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 2
Chunk 174
---
 30, 2025 and 2024:

    Three
    Months Ended June 30, 2025 and 2024

    2025

    2024

    $
    Change

    %
    Change

    OPERATING EXPENSES

    General and administrative expenses
     
    $
    1,110,084

    $
    1,209,874

    $
    (99,790
    ) 

    (8
    )%

    Research and development

    514,814

    12,955

    501,859

    3,874
    %

    Professional fees

    1,605,525

    541,257

    1,064,268

    197
    %

    Total operating expenses

    3,230,423

    1,764,086

    1,466,337

    83
    %

    Loss from operations

    (3,230,423
    )

    (1,764,086
    )

    (1,466,337
    ) 

    (83
    )%

    Other expense

    (218,516
    )

    (7,533
    )

    (210,983
    ) 

    (2,801
    )%

    Net loss before provision for income taxes

    (3,448,939
    )

    (1,771,619
    )

    (1,677,320
    )

    (95
    )%

    Provision for income taxes

    —

    —

    —

    NA

    Net loss
     
    $
    (3,448,939
    )

    (1,771,619
    )

    (1,677,320
    )

    (95
    )%

36 

Operating
Expenses

Our
operating expenses consist of general and administrative expenses, research and development expenses and professional fees.

General
and Administrative Expenses

We
incurred general and administrative expenses for the three months ended June 30, 2025 and 2024 of $1,110,084 and $1,209,874, respectively.
For the three months ended June 30, 2025, compared to the same period in 2024, this represented a decrease of $99,790, or 8%,
primarily as a result of a decrease of